Our Mission

Improve patient outcomes by translating whole-genome sequence and structure information into the most comprehensive insights possible for cancer therapy selection

Our Team

We are united by a singular focus: ensuring breakthrough therapies reach the patients they were created for. To us, there is no greater tragedy than a missed biomarker that could have given someone with cancer a fighting chance. By pairing deep technical know-how with unwavering empathy for the person behind every sample, we build diagnostics that guide patients to the care they deserve.

Our Story

Arima’s journey began in 2015, developing tools to give scientists an unprecedented window into how DNA is organized and behaves in three dimensions. Everything changed in early 2022, when a biopsy from a teenage girl with glioblastoma reached our lab.

Multiple rounds of exhaustive DNA- and RNA-profiling at a leading academic center had failed to uncover an actionable driver; time was running out. Our assay found what the others had missed – what they never could have found – because they lacked the comprehensive view we are able to provide. The patient began a new treatment and, remarkably, continues to do well.

That moment crystallized our purpose: cancer diagnostics must evolve to capture the full complexity of the genome. Since then, Arima has launched the Aventa clinical laboratory, empowering physicians across the United States to uncover fusions and rearrangements that other tests overlook. With every sample we process, the goal is the same: give clinicians the complete genomic picture they need so that no patient is left without options.